Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 1.97% is 49% below its 5-year average of 3.83%, near the low end of its 5-year range (-0.87%–9.15%).
10.05% below its 12-month average of 2.19%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-07-05): 0.43%.
RETURN ON ASSETS (ROA)
1.97%
RETURN ON ASSETS (ROA) AVG TTM
2.19%
RETURN ON ASSETS (ROA) AVG 3Y
1.89%
RETURN ON ASSETS (ROA) AVG 5Y
3.83%
RETURN ON ASSETS (ROA) AVG 10Y
3.90%
RETURN ON ASSETS (ROA) AVG 15Y
3.52%
RETURN ON ASSETS (ROA) AVG 20Y
3.31%
CURRENT VS TTM AVG
-10.05%
CURRENT VS 3Y AVG
+4.51%
CURRENT VS 5Y AVG
-48.56%
CURRENT VS 10Y AVG
-49.46%
CURRENT VS 15Y AVG
-43.97%
CURRENT VS 20Y AVG
-40.57%
SECTOR MEDIAN · HEALTHCARE
5.14%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
-61.67%
vs the sector median at left
Revvity, Inc.
Market Cap
$15.64B
Return on Assets (ROA)
1.97%
TTM Avg
2.19%
3Y Avg
1.89%
5Y Avg
3.83%
Market Cap
$15.60B
Return on Assets (ROA)
10.07%
TTM Avg
7.10%
3Y Avg
8.43%
5Y Avg
7.35%
Market Cap
$14.30B
Return on Assets (ROA)
34.50%
TTM Avg
22.59%
3Y Avg
17.42%
5Y Avg
13.40%
Market Cap
$17.32B
Return on Assets (ROA)
23.89%
TTM Avg
21.05%
3Y Avg
19.32%
5Y Avg
16.45%
Market Cap
$13.14B
Return on Assets (ROA)
-3.17%
TTM Avg
-0.94%
3Y Avg
2.58%
5Y Avg
3.75%
Market Cap
$12.54B
Return on Assets (ROA)
8.13%
TTM Avg
5.32%
3Y Avg
4.08%
5Y Avg
2.47%
Market Cap
$12.26B
Return on Assets (ROA)
-5.37%
TTM Avg
-3.64%
3Y Avg
-1.62%
5Y Avg
0.47%
Market Cap
$19.04B
Return on Assets (ROA)
3.54%
TTM Avg
3.64%
3Y Avg
3.29%
5Y Avg
2.38%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Revvity, Inc. (RVTY) | $15.64B | 1.97% | 2.19% | 1.89% | 3.83% |
| Solventum Corporation (SOLV)vs › | $15.60B | 10.07% | 7.10% | 8.43% | 7.35% |
| Exelixis, Inc. (EXEL)vs › | $14.30B | 34.50% | 22.59% | 17.42% | 13.40% |
| Medpace Holdings, Inc. (MEDP)vs › | $17.32B | 23.89% | 21.05% | 19.32% | 16.45% |
| Charles River Laboratories International, Inc. (CRL)vs › | $13.14B | -3.17% | -0.94% | 2.58% | 3.75% |
| Penumbra, Inc. (PEN)vs › | $12.54B | 8.13% | 5.32% | 4.08% | 2.47% |
| Baxter International Inc. (BAX)vs › | $12.26B | -5.37% | -3.64% | -1.62% | 0.47% |
| DaVita Inc. (DVA)vs › | $12.26B | 4.79% | 4.84% | 4.27% | 4.56% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $19.04B | 3.54% | 3.64% | 3.29% | 2.38% |
| Encompass Health Corporation (EHC)vs › | $12.10B | 8.33% | 7.48% | 6.38% | 5.99% |
ROA
2.0%
ROE
3.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-28 | 1.99% |
| 2024-12-29 | 2.39% |
| 2023-12-31 | -0.87% |
| 2022-12-31 | 4.03% |
| 2021-12-31 | 6.29% |
| 2020-12-31 | 9.15% |
| 2019-12-31 | 3.48% |
| 2018-12-31 | 4.00% |
| 2017-12-31 | 1.86% |
| 2016-12-31 | 5.46% |
| 2015-12-31 | 5.10% |
| 2014-12-31 | 3.83% |
| 2013-12-31 | 4.25% |
| 2012-12-31 | 1.75% |
| 2011-12-31 | 0.03% |
| 2010-12-31 | 11.96% |
| 2009-12-31 | 2.80% |
| 2008-12-31 | 4.38% |
| 2007-12-31 | 4.51% |
| 2006-12-31 | 4.67% |
| 2005-12-31 | 3.03% |
| 2004-12-31 | 2.95% |
| 2003-12-31 | 2.03% |
| 2002-12-31 | -0.15% |
| 2001-12-31 | -0.02% |
| 2000-12-31 | 4.14% |
| 1999-12-31 | 1.66% |
| 1998-12-31 | 8.96% |
| 1997-12-31 | 4.05% |
| 1996-12-31 | 7.32% |
